<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Bcl-2 proto-oncogene was discovered at the t(14;18) breakpoint found in most follicular B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and some diffuse large-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Bcl-2 is unique among proto-oncogenes, being localized to mitochondria and extending cell survival by blocking programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined Bcl-2 protein expression in 82 hematologic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and reactive lymphoid processes </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with Bcl-2 rearrangement demonstrated high levels of Bcl-2 protein </plain></SENT>
<SENT sid="4" pm="."><plain>However, most follicular and diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> without Bcl-2 rearrangement also displayed intense Bcl-2 staining </plain></SENT>
<SENT sid="5" pm="."><plain>In these cases, mechanisms other than classic translocation may be deregulation Bcl-2 </plain></SENT>
<SENT sid="6" pm="."><plain>The pattern of Bcl-2 staining in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is the inverse of the pattern in reactive <z:mpath ids='MPATH_134'>hyperplasia</z:mpath>, confirming a role for Bcl-2 immunolocalization in routine diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>Small lymphocytic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, expressed intermediate levels of Bcl-2 </plain></SENT>
<SENT sid="8" pm="."><plain>Bcl-2 protein varied in <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell dyscrasias</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Bcl-2 protein levels in T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> reflected their corresponding stage of development </plain></SENT>
<SENT sid="10" pm="."><plain>No substantial Bcl-2 was present in the Reed-Sternberg cells of nodular sclerosing <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0005506'>Chronic myelogenous leukemia</z:hpo> was strongly positive for Bcl-2, consistent with the presence of Bcl-2 in <z:mpath ids='MPATH_458'>normal</z:mpath> myeloid progenitors </plain></SENT>
<SENT sid="12" pm="."><plain>Immunohistochemistry identified an expanded spectrum of hematopoietic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in which Bcl-2 may provide a cell survival advantage </plain></SENT>
</text></document>